Asia Pacific Generic Oncology Sterile Injectable Market
- 2026 年市場規模
- USD 17.5 Bn
- 2033 年預估規模
- USD 27.3 Bn
- 年複合成長率 CAGR
- 13.1%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Asia Pacific Generic Oncology Sterile Injectable Market, By Drug Type (Monoclonal Antibodies, Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Cytokines, and Peptide Hormones), By Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (Asia Pacific)
報告摘要
Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectable products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India and China. Therefore, governments of such countries are focusing on reducing the cost of medications and increasing its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer products by 86% in March 2017.
Market Dynamics
Various India-based pharmaceutical companies are intended towards expansion of their distribution globally, leading to the generation of significant revenue which will aid in growth of generic oncology sterile injectables market in the region. For instance, in July 2017, Alembic Pharmaceuticals, an India-based company, inaugurated its manufacturing facility for generic oncology products in Gujarat that will cater to the markets in the Middle East, Africa, Asia, and North America. The manufacturing site has a capacity for 60 million tablets and capsules, and around 20 million vials capacity for liquid injectable and lyophilized products.
Similarly, in 2016, Sun Pharma expanded the company’s presence in Japan with the acquisition of 14 prescribed brands from Novartis for US$ 293 Mn.
Furthermore, Lupin, a pharmaceutical Indian firm active in Japan, announced in February 2016 that its subsidiary Kyowa is setting up a manufacturing plant in Tottori, to meet the rising demand for generics in Japan, where generics represent 49% of drug sales volume marking the second-largest drug market, after the U.S., in the world.
Key features of the study
• This report provides an in-depth analysis of Asia Pacific generic oncology sterile injectable market, provides market size (US$ million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the Asia Pacific generic oncology sterile injectable market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Eli Lily and Company, Biocon Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Baxter International Inc., Hikma Pharmaceuticals, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The Asia Pacific generic oncology sterile injectable market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Asia Pacific generic oncology sterile injectable market
Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o Monoclonal Antibodies
o Chemotherapy
Alkylating Agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Others
o Cytokines
o Peptide Hormones
• By Disease Indication (Revenue, USD Bn, 2021-2033)
o Ovarian Cancer
o Breast Cancer
o Lung Cancer
o Pancreatic Cancer
o Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
• Key Players
o Eli Lily and Company
o Biocon Ltd.
o Sun Pharmaceutical Industries Ltd.
o Reddy’s Laboratories Ltd
o Baxter International Inc.
o Hikma Pharmaceuticals
o Mylan N.V.
o Sandoz International GmbH
o Teva Pharmaceutical Industries Ltd.
o Pfizer Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Industry Trends
o Pipeline Analysis
o Patent Expiry
o Product Launch/ Approval
o Mergers And Acquisition Scenario
o Regulatory Scenario
o PEST Analysis
4. Asia Pacific Generic Oncology Sterile Injectable Market, By Drug Type, 2021-2033 (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Alkylating Agents
o Antimetabolites
o Plant Alkaloids
o Antitumor Antibiotics
o Others
o Cytokines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Peptide Hormones
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Asia Pacific Generic Oncology Sterile Injectable Market, By Disease Indication, 2021-2033 (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Ovarian Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Pancreatic Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Asia Pacific Generic Oncology Sterile Injectable Market, By Distribution Channel, 2021-2033 (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Asia Pacific Generic Oncology Sterile Injectable Market, By Country, 2021-2033 (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022 - 2033
Regional Trends
o China
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o India
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o Japan
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o Australia
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o South Korea
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o ASEAN
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
o Rest of Asia Pacific
Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
8. Competitive Landscape
o Company Profiles
Eli Lily and Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Biocon Ltd.
Sun Pharmaceutical Industries Ltd.
Reddy’s Laboratories Ltd
Baxter International Inc.
Hikma Pharmaceuticals
Mylan N.V.
Sandoz International GmbH
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
9. Section
o Research Methodology
o About us
o Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們